Lyfebulb

We are excited to announce the winner of the inaugural JPM Asset Management Life Sciences Innovation Summit as Rayees R. of Harmonic Discovery as well as our runner-up Chun-Hao Huang of Algen Biotechnologies. Dr Steve Squinto and his team at the JPM Life Sciences Private Capital group originating the idea to source global talent to continue to grow the emerging biotech hub in the Emirati region close to one year ago. Together as a team, we completed the challenge over the past few days in Abu Dhabi. This is only the beginning of what will come! Thank you to our partner the Department of Health Abu Dhabi, our lead sponsor Blue Horizon / United Al Saqer Group as well as our supporters Thermo Fisher Scientific, Salam Capital and JPM commercial bank. We were graciously hosted by Cleveland Clinic Abu Dhabi which showcased its world class patient care and science to all finalists. All finalists presented compelling cases of innovation and ability to address unmet needs, but what stood out in our winners were the clear case of how to improve patient care in the Emirati region and the innovative level of the technology. Thank you also to our experienced judges Dr Laurie Glimcher (CEO Dana Farber), Dr Shahrukh Hashmi (DOH Abu Dhabi), Dr Yasmine Hayek Kobeissi Ph.D (Blue Horizon), Dr Jorge A. Guzman (CEO Cleveland Clinic Abu Dhabi), Anya Schiess (JPM) and Dr Zaher Walid Zaher (CEO CareXso). Nabil Kobeissi and his team at Blue Horizon/United Al Saquer group surprised the group by announcing the intention of BHA to invest in the winner of the challenge as well as to evaluate all finalists for further commitments. Masdar City provided business licenses to all finalists so that they can set up offices in the region. https://lnkd.in/e6CmvPG2 #innovation #biotech #lifesciences #emirati #sicklecelldisease #crispr #ai #oncology Stephen Squinto Gaurav Gupta Department of Health Abu Dhabi Dana-Farber Cancer Institute Lyfebulb Leslie Simmons Brille Jamie Haight Olivia Schwern Joanna Rowe Evan Sotiriou Abby Mueller Patrik Strömberg Natalie J. Galant, PhD Seah Lim Cesare Spadoni Patient Care America Dongxing Zha Jaden Hyungseok C. Matthew Lorence Anton Malyshev SaudiVax Mohamed Mostafa

The life sciences space has changed over the past two years - raising funds has become much harder, fewer companies are going public, and even getting started as an entrepreneur out of a laboratory in academia takes more effort than maybe ever. That is why we are so excited to be bringing you this opportunity to network with company builders and investors through our initiative with Stephen Squinto and his brilliant team and advisors. Advisors include Laurie Glimcher and team members such as Gaurav Gupta . If you are interested in starting, building or just developing your company further, apply to our innovation challenge and do not hesitate to message me re questions! #innovation #lifesciences #biotechnology #companyformation David Hung, M.D. Leslie Simmons Brille Lyfebulb Stacey Gandler

Dialysis is a bridge to transplant, not a destination That has always been the premise for the very large dialysis industry, especially since the American people (Medicare) support ESRD patients. Lately, the numbers just do not reflect that promise, due to the lack of organs and the inability of dialysis centers to get patients ready for the transplant process. Only 25k kidney transplants are done every year, while 500k patients are on dialysis and at least 100k patients die each year while on dialysis. The cost for dialysis per year for Medicare is close to $100k, which is a fraction of what commercial insurance has to pay, and a transplant patient costs society less than $20k per year after the first year which includes the surgery. I had the privilege of attending the NOBLE Capital Markets conference in South Florida yesterday and presented on a Star-studded panel including luminaries such as surgeons Piotr Witkowski and Muhammad Mohiuddin, as well as entrepreneur and executive David-Alexandre "DA" Gros. Nathan Cali moderated our panel and we could have spent an additional hour, at least, discussing the promise of xeno transplantation (pig organs), cell transplant (islet transplant for t1d) and new immune modulation applicable to both modalities in addition to current allo transplantation (getting a kidney from a deceased donor or a living donor). The future is promising but we need patients, providers, industry, payers and regulators to come together as one voice to structure a path. Importantly, as patients and advocates we can never stop challenging the status quo - we deserve better! Lyfebulb Tom Mueller Veloxis Pharmaceuticals, Inc. Eledon Pharmaceuticals, Inc. Erik Berglund CSL Kevin Kovaleski Riccardo Braglia Stephen Squinto Leslie Simmons Brille Michael Mittelman Bruce Culleton Ulf Meier-Kriesche, MD Amanda Klein Soren Tulstrup CareDx, Inc. Crystal King Phil Keough Jamie Haight United Therapeutics Corporation Hansa Biopharma TransMedics, Inc. Dalton Shaull Joseph Scalea, MD Sana Biotechnology, Inc. Paul Brunetta Alexandra Bowden

"We are thrilled to be collaborating with Blue Horizon to really shine the light on the opportunities for emerging growth biopharma companies in Abu Dhabi," stated Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital. Lyfebulb

Attention entrepreneurs worldwide! We just launched a global innovation challenge, sponsored by J.P. Morgan Life Sciences Private Capital and Blue Horizon Advisors, to source entrepreneurs in life sciences and seed the growth of emerging scientific innovation in the UAE. We are seeking applicants with therapeutic solutions to better manage and care for diseases that are prevalent in the Emirati region. Examples of these diseases include, but are not limited to, diabetes, obesity, cardiometabolic disease, oncology, sickle cell anemia, cystic fibrosis, lysosomal storage disease, and rare monogenic disorders. We hope to see your application – read our press release: https://lnkd.in/eeCBVYzg or check out our website: https://lnkd.in/esBVbPDV to learn more. If you have any questions, please reach out to the Lyfebulb team. J.P. Morgan Asset Management Blue Horizon Advisors Stephen Squinto Karin Hehenberger Leslie Simmons Brille Jamie Haight

Today marked an important day in transplant medicine, when the FDA had scheduled not one but two meetings focused on the future of patient outcomes. The first one being a workshop entitled Endpoints and Trial Designs to Advance Drug Development in Kidney Transplantation and the second being around Xenotransplantation. For advocates, it was hard to choose, but Lyfebulb attended the former one with the belief that we would finally see a clear path for the many emerging companies in this space to have a chance to enter the market place and importantly give patients options. Currently we are treated with drug combinations from two decades ago, that enable us to keep our grafts to a very high extent during the first year after transplant, but have not meaningfully improved long term graft survival OR reduced the significant risks with existing drugs. There is hope among the patient community that one transplant might last a lifetime, but for many of us we are already on our second or third organ and yet we are only at the midpoint of our lives. There is hope among the patient community that we could one day avoid the deadly side effects that include skin cancers, lymphoma, infections and cardiovascular events, but also the “less” serious ones, yet those limit our ability to live life to its fullest: hair loss, diarrhea, tremors, mental confusion, anxiety and severe headaches are present in close to half of our peers. So what was the conclusion? Not easy to understand, yet the presentations were rigorous and the QA sessions active. We heard nothing regarding a timeline for a decision with respect to simply add a secondary efficacy endpoint (ibox including eGFR) that remarkably has already been conditionally approved by the European authorities. The report card so far: No new drugs since 2011 No phase three trials ongoing Large pharma companies like Novartis recently dismantling their transplant division, and venture capital still looking to oncology and autoimmunity vs transplantation. We deserve more #transplantation #drugdevelopment #fda #patientvoice #innovation American Society of Nephrology David-Alexandre "DA" Gros Ulf Meier-Kriesche, MD Simon Tremblay, PharmD, PhD Erik Berglund Lloyd Ratner MD MPH FACS FICS(Hon) Amanda Klein, PharmD, CDCES (she-her) Memo Therapeutics AG American Association of Kidney Patients Glenda V. Roberts Molly J. McCarthy Michael Mittelman Sharron Rouse Jeanmarie Ferguson Kevin Longino Hansa Biopharma CareDx, Inc. Eurofins Transplant Genomics ITBMed Veloxis Pharmaceuticals, Inc. Jonathan Sadeh, M.D., M.Sc. Stephen Squinto Tom Mueller Richard Formica American Society of Transplant Surgeons American Society of Transplantation Sanofi Vertex Pharmaceuticals Sana Biotechnology, Inc. Astellas Pharma US Lorrinda Gray-Davis Riccardo Braglia Lisa Hehenberger Leslie Simmons Brille

In recent years, scientific cancer research and therapies have made tremendous strides to improve outcomes and life expectancy. But, what does this mean for quality of life? Have symptoms and side effects of treatments improved too? Join us on November 1st @ 5pm EST to discuss this topic with Dr. Diane Reidy-Lagunes, an oncologist at Memorial Sloan Kettering Cancer Center, and Leah Evert, cancer survivor and co-founder of The Willow Foundation, a non-profit that provides funding to researchers to improve outcomes for cancer patients.